Pharmacist-Driven Implementation of Fast Identification and Antimicrobial Susceptibility Testing Improves Outcomes for Patients with Gram-Negative Bacteremia and Candidemia
Overview
Affiliations
Bloodstream infections (BSI) are associated with increased morbidity and mortality, especially when caused by Gram-negative or fungal pathogens. The objective of this study was to assess the impact of fast identification-antimicrobial susceptibility testing (ID/AST) with the Accelerate Pheno system (AXDX) from May 2018 to December 2018 on antibiotic therapy and patient outcomes. A pre-post quasiexperimental study of 200 patients (100 pre-AXDX implementation and 100 post-AXDX implementation) was conducted. The primary endpoints measured were time to first antibiotic intervention, time to most targeted antibiotic therapy, and 14-day hospital mortality. Secondary endpoints included hospital and intensive care unit (ICU) length of stay (LOS), antibiotic intensity score at 96 h, and 30-day readmission rates. Of 100 patients with Gram-negative bacteremia or candidemia in each cohort, 84 in the preimplementation group and 89 in the AXDX group met all inclusion criteria. The AXDX group had a decreased time to first antibiotic intervention (26.3 versus 8.0, = 0.003), hours to most targeted therapy (14.4 versus 9, = 0.03), hospital LOS (6 versus 8, = 0.002), and average antibiotic intensity score at 96 h (16 versus 12, = 0.002). Both groups had a comparable 14-day mortality (0% versus 3.6%, = 0.11). In this analysis of patients with Gram-negative bacteremia or candidemia, fast ID/AST implementation was associated with decreased hospital LOS, decreased use of broad-spectrum antibiotics, shortened time to targeted therapy, and an improved utilization of antibiotics within the first 96 h of therapy.
MacVane S, Dwivedi H J Antimicrob Chemother. 2024; 79(Supplement_1):i13-i25.
PMID: 39298359 PMC: 11412245. DOI: 10.1093/jac/dkae282.
Ventres J, Ting M, Parente D, Rogers R, Norris A, Benitez G Open Forum Infect Dis. 2024; 11(9):ofae477.
PMID: 39263216 PMC: 11389609. DOI: 10.1093/ofid/ofae477.
de Lorenzi-Tognon M, Schrenzel J Sci Rep. 2024; 14(1):9776.
PMID: 38684841 PMC: 11059348. DOI: 10.1038/s41598-024-60041-6.
Brosh-Nissimov T, Tzur A, Grupel D, Cahan A, Maaravi N, Heled-Akiva M Ann Clin Microbiol Antimicrob. 2023; 22(1):62.
PMID: 37516885 PMC: 10387206. DOI: 10.1186/s12941-023-00619-6.
Fratoni A, Kois A, Colmerauer J, Linder K, Nicolau D, Kuti J Open Forum Infect Dis. 2022; 9(9):ofac468.
PMID: 36176570 PMC: 9494375. DOI: 10.1093/ofid/ofac468.